USANA Health Sciences Inc. (USNA) Position Reduced by Alps Advisors Inc.
Alps Advisors Inc. lowered its position in USANA Health Sciences Inc. (NYSE:USNA) by 6.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,360 shares of the company’s stock after selling 248 shares during the period. Alps Advisors Inc.’s holdings in USANA Health Sciences were worth $374,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in the company. Teachers Advisors Inc. increased its position in USANA Health Sciences by 30.6% in the first quarter. Teachers Advisors Inc. now owns 87,383 shares of the company’s stock valued at $10,610,000 after buying an additional 20,496 shares in the last quarter. Old Mutual Global Investors UK Ltd. increased its position in USANA Health Sciences by 174.8% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 59,105 shares of the company’s stock valued at $6,586,000 after buying an additional 37,595 shares in the last quarter. Prudential Financial Inc. increased its position in USANA Health Sciences by 48.3% in the first quarter. Prudential Financial Inc. now owns 31,317 shares of the company’s stock valued at $3,802,000 after buying an additional 10,199 shares in the last quarter. Barclays PLC increased its position in USANA Health Sciences by 1,181.8% in the first quarter. Barclays PLC now owns 17,432 shares of the company’s stock valued at $2,109,000 after buying an additional 16,072 shares in the last quarter. Finally, UBS Group AG increased its position in USANA Health Sciences by 138.5% in the first quarter. UBS Group AG now owns 8,779 shares of the company’s stock valued at $1,066,000 after buying an additional 5,098 shares in the last quarter. Institutional investors and hedge funds own 41.86% of the company’s stock.
USANA Health Sciences Inc. (NYSE:USNA) traded down 1.25% on Tuesday, hitting $146.40. The stock had a trading volume of 135,723 shares. USANA Health Sciences Inc. has a 1-year low of $92.00 and a 1-year high of $150.00. The company’s 50 day moving average is $138.21 and its 200-day moving average is $126.84. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of 19.30 and a beta of 1.34.
USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, July 26th. The company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.05 by $0.02. The company earned $258.50 million during the quarter, compared to the consensus estimate of $256.66 million. USANA Health Sciences had a net margin of 10.07% and a return on equity of 34.15%. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.92 earnings per share. On average, analysts forecast that USANA Health Sciences Inc. will post $8.10 EPS for the current year.
Several research analysts have issued reports on USNA shares. Zacks Investment Research raised USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective on the stock in a report on Saturday, July 30th. DA Davidson increased their price target on USANA Health Sciences from $135.00 to $150.00 and gave the company a “neutral” rating in a research note on Thursday, July 28th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $149.11.
In related news, major shareholder Global Ltd Gull sold 10,000 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $134.67, for a total value of $1,346,700.00. Following the transaction, the insider now directly owns 6,329,110 shares of the company’s stock, valued at $852,341,243.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Paul A. Jones sold 5,067 shares of USANA Health Sciences stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $138.50, for a total transaction of $701,779.50. Following the completion of the transaction, the chief financial officer now directly owns 5,067 shares in the company, valued at $701,779.50. The disclosure for this sale can be found here. 57.00% of the stock is currently owned by corporate insiders.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences Inc. (NYSE:USNA).
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.